The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Share News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 17.75
Bid: 17.00
Ask: 18.50
Change: 4.00 (29.09%)
Spread: 1.50 (8.824%)
Open: 16.25
High: 18.25
Low: 15.25
Prev. Close: 13.75
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks rise ahead of US Fed meeting minutes

Wed, 25th May 2022 17:06

(Alliance News) - Stocks in London ended mostly higher on Wednesday as market participants look ahead to the latest minutes from the US Federal Reserve at 1900 BST.

Investors are awaiting the Fed's next move on interest rates, with expectations for more half-point hikes to come as officials struggle to bring inflation down from four-decade highs.

At its most recent meeting, the Fed decided to raise interest rates by 50 basis points, as expected.

It was the first time the US central bank had hiked rates by a half-point in one step since 2000, and it took the federal funds rate to a range of 0.75% to 1.00%.

The FTSE 100 index closed up 38.40 points, or 0.5%, at 7,522.75. The mid-cap FTSE 250 index closed up 84.22 points, or 0.4%, at 19,934.04. The AIM All-Share index closed down 2.36 points, or 0.3%, at 952.93.

The Cboe UK 100 index closed up 0.6% at 750.63. The Cboe 250 ended up 0.4% at 17,675.79 and the Cboe Small Companies finished 0.3% lower at 14,567.59.

In mainland Europe, the CAC 40 stock index in Paris closed up 0.7%, while the DAX 40 in Frankfurt ended 0.6%.

"Traders are a little optimistic ahead of the release of the minutes from the recent Federal Reserve meeting, where rates were hiked by 0.5%. In March, the US central bank lifted rates by 25 basis points, so the 50-basis hike a few weeks ago showed us the bank are determined to tackle the high level of inflation," said Equiti Capital analyst David Madden.

In the FTSE 100, SSE ended the best performer, up 5.7%, after the power utility reported rising earnings and lifted its payout.

In the financial year that ended March 31, revenue climbed 42% to GBP16.91 billion from GBP11.87 billion. Pretax profit rose 44% to GBP3.48 billion from GBP2.42 billion. Adjusted earnings per share grew by 22% to 95.4 pence, within guidance, from 78.4p.

The adjusted EPS figure has been tipped to rise to "at least" 120p for the new year. For the five-year period to financial 2026, it expects compound annual adjusted EPS growth of between 7% and 10%.

SSE hiked its payout by 5.8% to 85.7p from 81.0p. SSE recently kicked off plans for a sales process for its SSEN Transmission arm. This is expected to formally begin in the summer. SSE plans to sell a 25% stake in the electricity transmission network unit.

Imperial Brands closed up 3.6% after Goldman Sachs raised the tobacco company to 'buy' from 'neutral'.

At the other end of the large-caps, JD Sports Fashion ended the worst performer down 6.1%, after the athletic apparel retailer, just before the market close, said Executive Chair Peter Cowgill will step down with immediate effect following long-standing corporate governance issues.

JD said Helen Ashton and Kath Smith will become interim non-executive chair & interim chief executive officer respectively.

The retailer said the reshuffle was a consequence of a continuing review of its internal governance and controls, as it decided to accelerate the separation of the roles of chair and chief executive.

Severn Trent ended the second worst performer, down 3.1%. The water company reported increases in revenue and profit despite upward pressure on power and chemical costs as non-household consumption returned to pre-pandemic levels.

The Coventry-based company reported pretax profit of GBP506.2 million in the year ended March 31, up 7.5% against the GBP470.7 million achieved the prior year.

Turnover climbed 6.4% to GBP1.94 billion from GBP1.83 billion as non-household consumption returned to pre-pandemic levels and household consumption lowered. Severn Trent added that this figure was at the top of its expected range.

Looking forward, Severn Trent said it expects turnover for the current financial year to be between GBP1.97 billion and GBP2.02 billion. This would result in between 1.4% to 3.9% turnover growth year-on-year if achieved.

Prudential lost 2.1%. The insurer hired Manulife Financial Corp executive Anil Wadhwani as its new chief executive following the retirement of Mike Wells.

Wadhwani currently serves at Toronto-headquartered Manulife as CEO of Manulife Asia. Manulife operates in Canada and Asia as Manulife and in the US primarily through its John Hancock Financial unit.

Prior to Manulife, Wadhwani spent over two decades at Citigroup. He will take up the Prudential role on February 25 next year. Wadhwani is stepping into the role after Mike Wells retired earlier this year, with Mark FitzPatrick currently serving as interim CEO.

In the FTSE 250, Pets at Home ended the best performer, up 13%, after the pet products retailer posted a surging profit thanks to its "resilient" pet care unit as a boom in pet ownership helped it propel to record sales growth.

Pretax profit for the financial year March 31 rose 40% to GBP148.7 million from GBP106.3 million a year ago. Revenue climbed to GBP1.32 billion from GBP1.14 billion.

The Cheshire, England-based retailer declared a final dividend of 7.5 pence, bringing the total dividend to 11.8p per share, up 48% from 8.0p.

Meanwhile, British Gas-owner Centrica and chemical firm Johnson Matthey are set to return to the FTSE 100 index next month, replacing television broadcaster ITV and postal operator Royal Mail, according to indicative changes released by FTSE Russell on Tuesday.

All four companies have been in and out of London's blue-chip list in recent years. Meanwhile, online fashion retailer Asos will join the FTSE 250, following its move to the London Main Market from AIM. JLEN Environmental Assets Group replaced Clipper Logistics in the FTSE 250 on Tuesday, after GXO Logistics completed its acquisition of Clipper.

Elsewhere, Angle surged 61% after the medical diagnostics company said the US Food & Drug Administration cleared its Parsortix system for patients with metastatic breast cancer.

The pound was quoted at USD1.2547 at the London equities close, up from USD1.2518 at the close Tuesday.

The euro stood at USD1.0678 at the European equities close, down from USD1.0725. Against the yen, the dollar was trading at JPY127.31, up from JPY126.67.

Stocks in New York were higher at the London equities close. The DJIA was up 0.4%, the S&P 500 index up 0.6% and the Nasdaq Composite up 0.9%.

Major indices have fallen throughout most of 2022 so far, prompting debate on whether the market has bottomed out or is close to doing so.

Brent oil quoted at USD113.93 a barrel at the equities close, marginally lower from USD113.97 at the close Tuesday.

Gold stood at USD1,850.30 an ounce at the London equities close, lower against USD1,866.09 late Tuesday.

The economic events calendar on Thursday has US economic growth figures and the latest jobless claims numbers at 1330 BST.

The UK corporate calendar on Thursday has annual results from online automotive platform Auto Trader, water company United Utilities, speciality chemicals firm Johnson Matthey and stockbroker AJ Bell.

By Arvind Bhunjun; arvindbhunjun@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 10:52

AIM WINNERS & LOSERS: Fletcher King optimistic; Angle in Astra deal

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
3 May 2024 08:48

LONDON MARKET OPEN: Confident start before US jobs data

(Alliance News) - Stock prices in London opened higher on Friday, on the rising conviction that the afternoon's US jobs report will be softer, cooling some hawkish Federal Reserve interest rate expectations.

Read more
3 May 2024 07:58

Angle strikes supplier deal with AstraZeneca

(Sharecast News) - Liquid biopsy technology firm Angle has struck a supplier deal with pharmaceutical giant AstraZeneca to develop an androgen receptor detection assay to enhance prostate cancer studies.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
24 Apr 2024 17:06

CORRECT: No record close for FTSE 100; mixed trade in US

(Correcting day of the week in the opening sentence.)

Read more
24 Apr 2024 17:00

LONDON MARKET CLOSE: No record close for FTSE 100; mixed trade in US

(Alliance News) - Stock prices in London closed lower on Thursday, with the FTSE 100's recent rally taking a pause for breath, but not after hitting another record high.

Read more
24 Apr 2024 10:32

Angle shares jump on supplier agreement with with AstraZeneca

(Alliance News) - Angle PLC shares rose on Wednesday, after it signed a contract with AstraZeneca PLC.

Read more
24 Apr 2024 10:10

AIM WINNERS & LOSERS: Filtronic jumps as lifts outlook

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
22 Apr 2024 16:52

IN BRIEF: Angle granted patents in US and Europe for Cellkeep slide

Angle PLC - Surrey-based medical diagnostics provider - Says it has been granted a European and US patent for its CellKeep slide. "We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions....This is a significant technology advancement for the [circulating tumor cell] liquid biopsy field and another step towards enabling biomarker-guided precision medicine for people with cancer," says Chief Executive Officer Andrew Newland. The CellKeep slide was developed by Angle to reduce cell loss during the transfer of CTCs to the microscope slide and to protect the morphology of the harvested cells.

Read more
22 Apr 2024 06:59

Angle granted European patent for CellKeep, US patent imminent

(Sharecast News) - Liquid biopsy specialist Angle announced on Monday that it has received a European patent for its 'CellKeep' slide, as it anticipated the imminent grant of an equivalent US patent application.

Read more
22 Jan 2024 18:03

IN BRIEF: Angle highlights supportive data for DNA analysis tool

Angle PLC - Surrey-based medical diagnostics provider - Announces publication of a peer-reviewed paper in a special issue of the journal - "Current Issues in Molecular Biology" Special Issue: Advanced Solutions for Cancer Therapy. Article brings together supporting evidence for the additional and complementary information that can be obtained from circulating tumour cells, demonstrating the value of a dual analyte approach for both CTCs and ctDNA (fragments of DNA released mainly by dying cells). Angle recently announced breakthrough data for real-time parallel next generation sequencing DNA analysis of both ctDNA and CTCs from a single tube of patient blood, using a pan-cancer panel run on an Illumina NGS system.

Read more
4 Jan 2024 16:54

LONDON MARKET CLOSE: Stocks up ahead of US nonfarm payrolls

(Alliance News) - Stock prices in London closed higher on Thursday, as investors eye the latest US non-farms data.

Read more
4 Jan 2024 12:19

Angle shares soar following "breakthrough" cancer diagnostics results

(Alliance News) - Angle PLC on Thursday said that "breakthrough results" from its latest blood sample cancer trials would allow it to expand its product sales and pharma services.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.